Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma

Basit Öğe Kaydı
dc.contributor.authorDuraj, Tomas
dc.contributor.authorKalamian, Miriam
dc.contributor.authorZuccoli, Giulio
dc.contributor.authorMaroon, Joseph C.
dc.contributor.authorD'Agostino, Dominic P.
dc.contributor.authorScheck, Adrienne C.
dc.contributor.authorPoff, Angela
dc.contributor.authorWinter, Sebastian F.
dc.contributor.authorHu, Jethro
dc.contributor.authorKlement, Rainer J.
dc.contributor.authorHickson, Alicia
dc.contributor.authorLee, Derek C.
dc.contributor.authorCooper, Isabella
dc.contributor.authorKofler, Barbara
dc.contributor.authorSchwartz, Kenneth A.
dc.contributor.authorPhillips, Matthew C. L.
dc.contributor.authorChamp, Colin E.
dc.contributor.authorZupec-Kania, Beth
dc.contributor.authorTan-Shalaby, Jocelyn
dc.contributor.authorSerfaty, Fabiano M.
dc.contributor.authorOmene, Egiroh
dc.contributor.authorArismendi-Morillo, Gabriel
dc.contributor.authorKiebish, Mİchael
dc.contributor.authorCheng, Rİchard
dc.contributor.authorEl-Sakka, Ahmed M.
dc.contributor.authorPflueger, Axel
dc.contributor.authorMathews, Edward H.
dc.contributor.authorWorden, Donese
dc.contributor.authorShi, Hanping
dc.contributor.authorCincione, Raffaele Ivan
dc.contributor.authorSpinosa, Jean Pierre
dc.contributor.authorSlocum, Abdul Kadir
dc.contributor.authorİyikesici, Mehmet Salih
dc.contributor.authorYanagisawa, Atsuo
dc.contributor.authorPilkington, Geoffrey J.
dc.contributor.authorChaffee, Anthony
dc.contributor.authorAbdel-Hadi, Wafaa
dc.contributor.authorElsamman, Amr K.
dc.contributor.authorKlein, Pavel
dc.contributor.authorHagihara, Keisuke
dc.contributor.authorClemens, Zsofia
dc.contributor.authorYu, George W.
dc.contributor.authorEvangeliou, Athanasios E.
dc.contributor.authorNathan, Janak K.
dc.contributor.authorSmith, Kris
dc.contributor.authorFortin, David
dc.contributor.authorDietrich, Jorg
dc.contributor.authorMokherjee, Purna
dc.contributor.authorSeyfried, Thomas N.
dc.date.accessioned2024-12-10T11:29:12Z
dc.date.available2024-12-10T11:29:12Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractGlioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a universally lethal prognosis despite maximal standard therapies. Here, we present a consensus treatment protocol based on the metabolic requirements of GBM cells for the two major fermentable fuels: glucose and glutamine. Glucose is a source of carbon and ATP synthesis for tumor growth through glycolysis, while glutamine provides nitrogen, carbon, and ATP synthesis through glutaminolysis. As no tumor can grow without anabolic substrates or energy, the simultaneous targeting of glycolysis and glutaminolysis is expected to reduce the proliferation of most if not all GBM cells. Ketogenic metabolic therapy (KMT) leverages diet-drug combinations that inhibit glycolysis, glutaminolysis, and growth signaling while shifting energy metabolism to therapeutic ketosis. The glucose-ketone index (GKI) is a standardized biomarker for assessing biological compliance, ideally via real-time monitoring. KMT aims to increase substrate competition and normalize the tumor microenvironment through GKI-adjusted ketogenic diets, calorie restriction, and fasting, while also targeting glycolytic and glutaminolytic flux using specific metabolic inhibitors. Non-fermentable fuels, such as ketone bodies, fatty acids, or lactate, are comparatively less efficient in supporting the long-term bioenergetic and biosynthetic demands of cancer cell proliferation. The proposed strategy may be implemented as a synergistic metabolic priming baseline in GBM as well as other tumors driven by glycolysis and glutaminolysis, regardless of their residual mitochondrial function. Suggested best practices are provided to guide future KMT research in metabolic oncology, offering a shared, evidence-driven framework for observational and interventional studies.en_US
dc.identifier.citationDuraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., ... & Seyfried, T. N. (2024). Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC medicine, 22(1), 578. 10.1186/s12916-024-03775-4en_US
dc.identifier.issn1741-7015
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85211576729
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5079
dc.identifier.volume22en_US
dc.identifier.wosWOS:001370662100001
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİyikesici, Mehmet Salih
dc.language.isoen
dc.relation.ispartofBMC Medicine
dc.relation.isversionof10.1186/s12916-024-03775-4en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCanceren_US
dc.subjectGlioblastomaen_US
dc.subjectGlutaminolysisen_US
dc.subjectMetabolismen_US
dc.subjectPrecision medicineen_US
dc.subjectResearch designen_US
dc.subjectWarburg Effecten_US
dc.titleClinical research framework proposal for ketogenic metabolic therapy in glioblastoma
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12916_2024_Article_3775.pdf
Boyut:
6.74 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu